Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

10,880 total articles

Lemonade Expands Renters Insurance to Louisiana

Lemonade Expands Renters Insurance to Louisiana

Lemonade, a tech-driven insurance company listed on NYSE as LMND, has expanded its renters insurance product to Louisiana. The service offers customizable coverage through a mobile app at prices starting around $5 monthly, significantly lower than average market rates. This move marks another step in Lemonade's nationwide growth, targeting renters …

Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress

Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress

Kura Oncology and Kyowa Kirin will present updated Phase 1 KOMET-007 trial results showing high and durable response rates of ziftomenib in combination with standard chemotherapy (7+3) in newly diagnosed acute myeloid leukemia (AML) patients with NPM1 mutations or KMT2A rearrangements. The data feature a 96% complete response rate and deep molecula…

First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026

First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026

Geron Corporation announced the presentation of the first real-world evidence study of RYTELO (imetelstat) in patients with lower-risk myelodysplastic syndromes (LR-MDS) at the EHA 2026 Congress. The study, conducted at Moffitt Cancer Center, demonstrated safety and clinical efficacy consistent with the Phase 3 IMerge trial, including in heavily tr…

Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress

Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress

Cogent Biosciences announced multiple presentations at the European Hematology Association (EHA) 2026 Congress, including pivotal oral presentation data from the APEX trial of bezuclastinib in Advanced Systemic Mastocytosis and preclinical data for their JAK2 V617F inhibitor program. These presentations underscore the company's progress in developi…

Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2026 Congress

Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2026 Congress

Disc Medicine announced multiple presentations at the European Hematology Association (EHA) 2026 Congress, including an oral presentation of phase 2 RALLY-MF trial data for DISC-0974 targeting anemia in myelofibrosis patients. The company also highlighted updates on bitopertin in erythropoietic protoporphyria (EPP) and ongoing trials for polycythem…

Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting

Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting

Caribou Biosciences announced that two of its investigational allogeneic CAR-T cell therapies, vispa-cel and CB-011, will be featured in oral presentations at the 2026 European Hematology Association Annual Meeting. These presentations will share updated clinical trial data demonstrating the therapies' potential in treating relapsed or refractory B…

Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel’s Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026

Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel’s Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026

Beam Therapeutics announced it will present updated Phase 1/2 clinical trial data for ristoglogene autogetemcel (risto-cel), an investigational gene-edited cell therapy aimed at treating sickle cell disease (SCD). The data underscores risto-cel's potential to restore red blood cell health and improve disease pathology by inducing fetal hemoglobin p…

Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias

Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias

Agios Pharmaceuticals announced new detailed data presentations of mitapivat at the 31st European Hematology Association Congress (EHA 2026). Results from the pivotal RISE UP Phase 3 trial in sickle cell disease demonstrate significant hemoglobin improvements and anti-hemolytic effects. Additional positive long-term data from ENERGIZE trials in tha…

Independent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits

Independent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits

Moleculin Biotech announced that an independent review by the Cleveland Clinic of pooled data from five clinical trials demonstrates that Annamycin, their next-generation anthracycline for relapsed/refractory acute myeloid leukemia (R/R AML), does not cause clinically significant cardiotoxicity even at cumulative doses exceeding conventional anthra…

Evaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congress

Evaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congress

Evaxion A/S announced that it will present new preclinical data for EVX-04, an AI-designed off-the-shelf therapeutic vaccine targeting endogenous retroviral antigens in acute myeloid leukemia (AML), at the European Hematology Association 2026 Congress. The data demonstrate EVX-04's immune response capabilities and tumor growth prevention in preclin…

Uniti Wholesale Accelerates with FastWaves™

Uniti Wholesale Accelerates with FastWaves™

Uniti Wholesale has quickly demonstrated strong demand for its FastWaves service, securing a customer for eight 400G circuits just two weeks after launch and delivering circuits in 14 days. FastWaves addresses the market need for faster wavelength delivery, particularly driven by AI workloads, hyperscalers, neocloud providers, and large enterprises…

New Study Finds 76% of Advertisers See Performance Gains from Agentic AI; 86% Would Allocate Up to a Quarter of Advertising Budget to the Open Web with the Right Agentic AI Solution

New Study Finds 76% of Advertisers See Performance Gains from Agentic AI; 86% Would Allocate Up to a Quarter of Advertising Budget to the Open Web with the Right Agentic AI Solution

Taboola released a study showing that 76% of advertisers have experienced performance improvements from agentic AI, predominantly within search and social platforms. However, 80% of advertisers are eager to expand AI-driven advertising beyond walled gardens to the open web, with 86% willing to allocate up to 25% of their budgets accordingly. The co…